Cargando…

Population-based study on use of chemotherapy in men with castration resistant prostate cancer

BACKGROUND. Chemotherapy prolongs life and relieves symptoms in men with castration resistant prostate cancer (CRPC). There is limited information on a population level on the use of chemotherapy for CRPC. MATERIAL AND METHODS. To assess the use of chemotherapy in men with CRPC we conducted a regist...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lissbrant, Ingela Franck, Garmo, Hans, Widmark, Anders, Stattin, Pär
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Informa Healthcare 2013
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3812701/ https://www.ncbi.nlm.nih.gov/pubmed/23427879 http://dx.doi.org/10.3109/0284186X.2013.770164

Ejemplares similares

The Value of Real-World Data in Understanding Prostate Cancer Risk and Improving Clinical Care: Examples from Swedish Registries
por: Beckmann, Kerri, et al.
Publicado: (2021)

Comparative Effectiveness of Different Radical Radiotherapy Treatment Regimens for Prostate Cancer: A Population-Based Cohort Study
por: Pettersson, Andreas, et al.
Publicado: (2020)

Population‐based study of long‐term functional outcomes after prostate cancer treatment
por: Carlsson, Sigrid, et al.
Publicado: (2015)

A drug comorbidity index to predict mortality in men with castration resistant prostate cancer
por: Fallara, Giuseppe, et al.
Publicado: (2021)

Observational study on time on treatment with abiraterone and enzalutamide
por: Fallara, Giuseppe, et al.
Publicado: (2020)

Public online reporting from a nationwide population‐based clinical prostate cancer register
por: Stattin, Pär, et al.
Publicado: (2018)

Modeling Disease Trajectories for Castration-resistant Prostate Cancer Using Nationwide Population-based Data
por: Ventimiglia, Eugenio, et al.
Publicado: (2022)

Long-term adverse effects after curative radiotherapy and radical prostatectomy: population-based nationwide register study
por: Fridriksson, Jón Ö., et al.
Publicado: (2016)

Risk of venous thromboembolism in men with prostate cancer compared with men in the general population: a nationwide population-based cohort study in Sweden
por: Balabanova, Yanina, et al.
Publicado: (2022)

Expression of Androgen Receptor Splice Variants in Prostate Cancer Bone Metastases is Associated with Castration-Resistance and Short Survival
por: Hörnberg, Emma, et al.
Publicado: (2011)

Population-based study of long-term anticoagulation for treatment and secondary prophylaxis of venous thromboembolism in men with prostate cancer in Sweden
por: Balabanova, Yanina, et al.
Publicado: (2022)

Causes of death in men with localized prostate cancer: a nationwide, population‐based study
por: Van Hemelrijck, Mieke, et al.
Publicado: (2015)

Temporal changes in cause‐specific death in men with localised prostate cancer treated with radical prostatectomy: a population‐based, nationwide study
por: Thomsen, Frederik B., et al.
Publicado: (2021)

Mini Review on the Use of Clinical Cancer Registers for Prostate Cancer: The National Prostate Cancer Register (NPCR) of Sweden
por: Cazzaniga, Walter, et al.
Publicado: (2019)

Comparison of Relative Survival and Cause-Specific Survival in Men With Prostate Cancer According to Age and Risk Category: A Nationwide, Population-Based Study
por: Orrason, Andri Wilberg, et al.
Publicado: (2021)

Androgen deprivation therapy and excess mortality in men with prostate cancer during the initial phase of the COVID-19 pandemic
por: Gedeborg, Rolf, et al.
Publicado: (2021)

Use of 5α-reductase inhibitors for lower urinary tract symptoms and risk of prostate cancer in Swedish men: nationwide, population based case-control study
por: Robinson, David, et al.
Publicado: (2013)

Prescription-based prediction of baseline mortality risk among older men
por: Gedeborg, Rolf, et al.
Publicado: (2020)

Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden
por: Van Hemelrijck, Mieke, et al.
Publicado: (2010)

Long-term Outcomes Among Men Undergoing Active Surveillance for Prostate Cancer in Sweden
por: Ventimiglia, Eugenio, et al.
Publicado: (2022)

Mortality following Hip Fracture in Men with Prostate Cancer
por: Van Hemelrijck, Mieke, et al.
Publicado: (2013)

Cohort Profile Update: The National Prostate Cancer Register of Sweden and Prostate Cancer data Base—a refined prostate cancer trajectory
por: Van Hemelrijck, Mieke, et al.
Publicado: (2016)

Association between atherogenic lipids and GnRH agonists for prostate cancer in men with T2DM: a nationwide, population-based cohort study in Sweden
por: Lin, E., et al.
Publicado: (2022)

Prediction of metastatic prostate cancer by prostate-specific antigen in combination with T stage and Gleason Grade: Nationwide, population-based register study
por: Thomsen, Frederik B., et al.
Publicado: (2020)

Exploring the association between use of gonadotropin releasing hormones agonists and prostate cancer diagnosis per se and diabetes control in men with type 2 diabetes mellitus: a nationwide, population-based cohort study
por: Lin, E., et al.
Publicado: (2021)

5-α reductase inhibitors, benign prostatic hyperplasia, and risk of male breast cancer
por: Robinson, David, et al.
Publicado: (2015)

Mortality in men with castration‐resistant prostate cancer—A long‐term follow‐up of a population‐based real‐world cohort
por: Khoshkar, Yashar, et al.
Publicado: (2021)

Association of Gonadotropin-Releasing Hormone Agonists for Prostate Cancer With Cardiovascular Disease Risk and Hypertension in Men With Diabetes
por: Lin, E., et al.
Publicado: (2022)

Association of type 2 diabetes mellitus and antidiabetic medication with risk of prostate cancer: a population-based case-control study
por: Lin, E., et al.
Publicado: (2020)

Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer
por: Crawley, Danielle, et al.
Publicado: (2016)

Variation in Prostate-Specific Antigen Testing Rates and Prostate Cancer Treatments and Outcomes in a National 20-Year Cohort
por: Bergengren, Oskar, et al.
Publicado: (2021)

Chronic inflammatory diseases, anti-inflammatory medications and risk of prostate cancer: a population-based case-control study
por: Beckmann, Kerri, et al.
Publicado: (2019)

Heterogeneity in risk of prostate cancer: A Swedish population‐based cohort study of competing risks and Type 2 diabetes mellitus
por: Häggström, Christel, et al.
Publicado: (2018)

Fatherhood status and risk of prostate cancer: Nationwide, population-based case–control study
por: Wirén, Sara M, et al.
Publicado: (2013)

Socioeconomic status and diagnosis, treatment, and mortality in men with prostate cancer. Nationwide population‐based study
por: Tomic, Katarina, et al.
Publicado: (2018)

Chemotherapy options in castration-resistant prostate cancer
por: Teply, Benjamin A., et al.
Publicado: (2016)

Predictive Factors for Premature Discontinuation of Docetaxel-Based Systemic Chemotherapy in Men With Castration-Resistant Prostate Cancer
por: Park, Seung Chol, et al.
Publicado: (2013)

Survival Trend in Individuals With De Novo Metastatic Prostate Cancer After the Introduction of Doublet Therapy
por: Corsini, Christian, et al.
Publicado: (2023)

Use of Antiepileptic Drugs and Risk of Prostate Cancer: A Nationwide Case-Control Study in Prostate Cancer Data Base Sweden
por: George, Gincy, et al.
Publicado: (2023)

Susceptibility to SARS‐Cov‐2 infection and risk for severe COVID‐19 in patients with prostate cancer on androgen deprivation therapy
por: Gedeborg, Rolf, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_75nfh3fo98bddaujokuoum13uq